News | January 10, 2025
Windlas Biotech’s new injectable facility receives GMP certification
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
The certification marks a new chapter in Windlas Biotech’s growth trajectory,
The site’s GMP Certification has been successfully renewed
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Cenexi is committed to working closely with the ANSM to address the observations
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
The company will receive GMP compliance certificate which will further help to accelerate the business growth across the globe
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Reaffirms Lupin’s commitment to sustainable resource management
Subscribe To Our Newsletter & Stay Updated
